Get the Stockscreener App
0.36
8.95%
-0.0354
Bolt Biotherapeutics Inc stock is traded at $0.36, with a volume of 280.86K.
It is down -8.95% in the last 24 hours and down -18.59% over the past month.
See More
Previous Close:
$0.3954
Open:
$0.3939
24h Volume:
280.86K
Relative Volume:
2.05
Market Cap:
$13.80M
Revenue:
$7.88M
Net Income/Loss:
$-69.20M
P/E Ratio:
-0.1967
EPS:
-1.83
Net Cash Flow:
$-69.73M
1W Performance:
-15.29%
1M Performance:
-18.59%
6M Performance:
-44.19%
1Y Performance:
-72.93%
1-Day Range:
$0.3534
$0.40
1-Week Range:
$0.3534
$0.4549
52-Week Range:
$0.3534
$1.3999
Bolt Biotherapeutics Inc Stock (BOLT) Company Profile
Name
Bolt Biotherapeutics Inc
Sector
Industry
Phone
650-665-9295
Address
900 CHESAPEAKE DRIVE, REDWOOD CITY
Compare BOLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BOLT
Bolt Biotherapeutics Inc
|
0.36 | 13.80M | 7.88M | -69.20M | -69.73M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Bolt Biotherapeutics Inc Stock (BOLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-02-21 | Initiated | Guggenheim | Buy |
| Mar-02-21 | Initiated | Morgan Stanley | Overweight |
| Mar-02-21 | Initiated | SVB Leerink | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
Bolt Biotherapeutics Inc Stock (BOLT) Latest News
Bolt Biotherapeutics stock hits 52-week low at $0.38 By Investing.com - Investing.com UK
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
What is HC Wainwright’s Estimate for BOLT Q1 Earnings? - Defense World
What is Leerink Partnrs’ Forecast for BOLT Q1 Earnings? - Defense World
Q3 Earnings Forecast for BOLT Issued By HC Wainwright - Defense World
H.C. Wainwright holds Neutral on Bolt Biotherapeutics stock By Investing.com - Investing.com Australia
H.C. Wainwright holds Neutral on Bolt Biotherapeutics stock - Investing.com India
Bolt Biotherapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Bolt Biotherapeutics Inc (BOLT) Q4 2024 Earnings: EPS Misses at -$0.42, Revenue Falls Short at $0 Million - GuruFocus
Bolt Biotherapeutics’ (BOLT) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Bolt Biotherapeutics (NASDAQ:BOLT) Given New $1.25 Price Target at Stifel Nicolaus - Defense World
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025 - The Manila Times
Groundbreaking Cancer Drug Trial Results: First-Ever Dectin-2 Agonist Data Revealed at AACR 2025 - Stock Titan
Stifel cuts Bolt Biotherapeutics stock price target to $1.25 By Investing.com - Investing.com Australia
Stifel cuts Bolt Biotherapeutics stock price target to $1.25 - Investing.com
Bolt Biotherapeutics Reports 2024 Financial Results and Updates - TipRanks
Bolt Biotherapeutics Inc.: Q4 Earnings Snapshot - The Washington Post
Bolt Biotherapeutics Updates on Clinical Trials and Financial Results, Anticipates Milestones for BDC-4182 and BDC-3042 - Nasdaq
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update - The Manila Times
BOLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Bolt Biotherapeutics stock hits 52-week low at $0.4 By Investing.com - Investing.com Australia
Bolt Biotherapeutics stock hits 52-week low at $0.4 - Investing.com India
Bolt Biotherapeutics (BOLT) to Release Earnings on Thursday - Defense World
Bolt Biotherapeutics stock hits 52-week low at $0.42 By Investing.com - Investing.com Australia
Bolt Biotherapeutics stock hits 52-week low at $0.42 - Investing.com India
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Bolt Biotherapeutics, Inc. (BOLT) - ACCESS Newswire
BOLT ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Bolt Biotherapeutics, Inc. Shareholders Who Lost Money - ACCESS Newswire
Bolt Biotherapeutics stock hits 52-week low at $0.46 By Investing.com - Investing.com Canada
Bolt Biotherapeutics stock hits 52-week low at $0.46 - Investing.com India
Bolt Biotherapeutics to Participate in Upcoming March Conferences - The Manila Times
Can Bolt Biotherapeutics' March Conference Appearances Signal New Clinical Developments? - StockTitan
Long Term Investors in Bolt Biotherapeutics, Inc. (NASDAQ: - openPR
Bolt Biotherapeutics, Inc. (BOLT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Biogen takes territorial rights to Stoke’s Dravet program: Deals Report - BioCentury
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc. - The Manila Times
Major Cancer Treatment Breakthrough: Bolt and Toray Target Caprin-1 in Solid Tumors - StockTitan
BOLT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Breast Cancer FDA Approvals, Pipeline Insights, Clinical Trials, Emerging Drugs and Companies | DelveInsight - The Globe and Mail
BOLT Stock Earnings: Bolt Biotherapeutics Misses EPS, Beats Revenue for Q2 2024 - MSN
Bolt Biotherapeutics shifts to Nasdaq Capital Market By Investing.com - Investing.com Nigeria
Bolt Biotherapeutics shifts to Nasdaq Capital Market - Investing.com India
Bolt Biotherapeutics, Inc. Announces Board and Committee Changes, Effective December 31, 2024 - Marketscreener.com
Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Shares Purchased by Fmr LLC - Defense World
Bolt Biotherapeutics Inc Stock (BOLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):